Guardant Health: High Revenue Dynamics in an Underserved Market
Reading Time: 2 minutes
The business model in focus: Guardant Health specializes in precision oncology and develops innovative liquid biopsy tests for cancer diagnostics. Through simple blood samples, these tests identify genetic changes in tumors to enable personalized cancer therapies and detect relapses early. Significant market potential: A report from RBC Capital Markets shows the organic potential: Currently, only 25% of patients with metastatic cancer in the US receive genomic profiling, which means that the core business operates in a highly underserved market....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
